Semaglutide first injection claims: what the science says

What did @noralisaz66 actually say?

Honestly, not much, at least not in this video. The transcript is almost entirely incoherent, a string of numbers and sounds that appear to be a transcription artifact rather than real speech. What we do have is the caption: she's 57, not diabetic, self-describes as "only fat," and is starting a generic compounded semaglutide at 0.25 mg. She promises a follow-up in 24 hours. That's the claim set we can actually work with.

The caption frames her situation plainly and without dramatic promises. No weight loss guarantees, no cure talk, no specific timelines. For a TikTok GLP-1 video, that's actually more restrained than average. The phrase "only fat" is blunt self-assessment, not a medical diagnosis, and the decision to start at the lowest available dose suggests at least some awareness of titration basics.

Does the science back this up?

Starting semaglutide at 0.25 mg weekly is exactly what the prescribing literature recommends for a reason: tolerability. The phase 3 STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) used a 16-week titration schedule starting at 0.25 mg before reaching the 2.4 mg maintenance dose used for weight management under the Wegovy label. That slow ramp exists to reduce nausea, vomiting, and GI distress, which are the most common early side effects.

For non-diabetic adults using semaglutide for weight management, the evidence is genuinely solid. STEP 1 showed an average 14.9% body weight reduction over 68 weeks in adults without diabetes. A 57-year-old woman using it for obesity, not blood sugar control, is using it in a context where clinical evidence supports the approach. The age group is relevant: postmenopausal women often face compounding metabolic challenges, and GLP-1 receptor agonists have shown efficacy across age groups in the STEP trials.

What did they get wrong (or right)?

She got the starting dose right, or at least consistent with clinical titration protocols. The 0.25 mg figure is not arbitrary. What we cannot evaluate is where this prescription came from, whether there was a proper clinical workup, and critically, whether the "generic version" she mentions is a compounded product from a 503A or 503B pharmacy. That matters enormously.

Compounded semaglutide is not the same as FDA-approved semaglutide. The FDA has explicitly stated that compounded versions have not been evaluated for safety, efficacy, or quality equivalence. Calling it a "generic version of Ozempic" is inaccurate framing. Generic drugs must meet FDA bioequivalence standards. Compounded semaglutide does not go through that process. This is not a technicality. It is a meaningful distinction that affects what patients can reasonably expect and what risks they're accepting. The video, through its caption, blurs this line without appearing to intend deception.

What should you actually know?

If you're considering semaglutide for weight management and you don't have type 2 diabetes, here's what the evidence actually shows. The STEP program trials consistently demonstrated clinically meaningful weight loss in people with obesity or overweight plus a weight-related condition, without requiring a diabetes diagnosis. This is a legitimate, well-studied use case.

However, the source of the medication matters. The FDA placed compounded semaglutide on its shortage list exemption, which allowed compounding pharmacies to produce it during drug shortages. As of 2024-2025, FDA has moved to end that exemption for semaglutide, signaling that compounded versions face increasing regulatory scrutiny. Patients using compounded products should be working with a licensed prescriber who is monitoring them, not just ordering from a website after a five-minute intake form.

Starting at 0.25 mg weekly is appropriate. Expecting dramatic results in 24 hours, the apparent premise of her follow-up video, is not realistic. Early weeks on semaglutide are largely about tolerance, not transformation.

• GLP-1 receptor agonists work by slowing gastric emptying, reducing appetite signaling, and increasing satiety hormones. Effects on hunger may be noticeable within days, but weight changes take weeks to months.
• Common early side effects include nausea, constipation, and fatigue. These are normal and usually manageable at low doses.
• Anyone starting semaglutide should have baseline labs, blood pressure monitoring, and a clear plan with a prescriber, not just a shipment in the mail.